First Brands Group debt targeted by Apollo Global Management - report
Investing.com - BNP Paribas Exane raised its price target on Phibro Animal Health Corp. (NASDAQ:PAHC) to $37.00 from $24.00 on Thursday, while maintaining a Neutral rating on the stock following the company’s fourth-quarter earnings beat and strong fiscal year 2026 guidance. The company’s stock has shown remarkable momentum, with an 84.3% year-to-date return according to InvestingPro data, while maintaining a "GREAT" overall financial health score.
The research firm noted that Phibro’s revenue growth and margin expansion momentum has been strong recently, with shares already up 19% following the earnings report. The company has demonstrated robust growth with a 27.37% revenue increase over the last twelve months. Despite the positive performance, BNP Paribas believes the current valuation fairly reflects the company’s prospects, trading at an EV/EBITDA multiple of 12.8x. InvestingPro’s analysis suggests the stock is currently trading above its Fair Value, with 12 additional exclusive insights available to subscribers.
The integration of Zoetis MFA remains a key growth driver for Phibro, with the firm highlighting that there has been no overlap or cannibalization with the legacy portfolio. BNP Paribas also noted that customer destocking has concluded, which should allow for cleaner growth in 2026. With a current ratio of 2.76, InvestingPro data shows the company maintains strong liquidity to support its growth initiatives. Discover comprehensive analysis in the Pro Research Report, available for over 1,400 US stocks.
Vaccines and Nutritional Specialties segments are expected to continue their growth momentum in fiscal year 2026, albeit at a slower pace compared to fiscal year 2025. The Vaccines segment is projected to grow approximately 7%, focusing more on incremental revenue rather than new customer acquisition in Brazil.
BNP Paribas increased its fiscal years 2026 and 2027 earnings per share estimates by approximately 16%, reflecting strong gross margins benefiting from favorable product mix and the Phibro Forward initiative. The firm also raised its fiscal year 2026 EV/EBITDA multiple to 9.5x from 8x, in line with historical averages but still representing about a 30% discount to competitor Elanco.
In other recent news, Phibro Animal Health Corporation reported stronger-than-expected financial results for the fourth quarter of 2025. The company achieved earnings per share (EPS) of $0.57, surpassing the anticipated $0.52, marking a 9.62% surprise. Revenue also exceeded expectations, reaching $378.7 million compared to the forecast of $362.24 million. These results highlight a significant performance for Phibro Animal Health, with both earnings and revenue outperforming projections. The company’s financial achievements have drawn attention from investors and analysts alike. While the earnings report is a major highlight, there have been no recent updates regarding mergers or acquisitions involving the company. Additionally, no new analyst upgrades or downgrades have been reported for Phibro Animal Health. These developments reflect the company’s current standing in the market based on its recent financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.